As a result, up to ¥330 million in assistance will be provided over a three-year period from August 1, 2025 to July 31, 2028.

Accelerating the practical application of functional raw materials derived from microalgae
(Head office: Kashiwa City, Chiba Prefecture; President: Shu Kimura; hereinafter "AlgalBio"), whose mission is "to contribute to the future of people and the Earth through the research and development of algae," has been selected by the Japan Science and Technology Agency (JST) for the "Support Program for Optimal Exploitation of Research Results (A-STEP (President: Shu Kimura; Head Office: Kashiwa City, Chiba Prefecture; hereinafter referred to as "Algar Bio") has been selected for the "Development of Highly Functional Raw Materials from Microalgae" development project under the "Support Program for Optimal Deployment of Research Results (A-STEP)" (repayment-type) implemented by the National Institute of Science and Technology Development (JST).
As a result, the company plans to receive up to ¥330 million in support over a three-year period from August 1, 2025 to July 31, 2028.
With this support, AlgarBio will work on the development of microalgae-derived raw materials with the aim of notifying them as food with functional claims. Specifically, the company aims to provide new product value derived from algae by acquiring data showing the efficacy of microalgae-derived ingredients, building evidence, elucidating their mechanism of action, and conducting legal and regulatory research for overseas development.
Functional materials derived from AlgarBio's microalgae library
AlgalBio, established in 2018, has built a microalgae biofoundry platform based on over 20 years of microalgae research at the University of Tokyo. utilizing a microalgae library of over 1260 strains of 100 species, we have promoted collaborative research with diverse industrial areas and in FY2024 In FY2024, over 34 joint projects were conducted.

In 2023, we released "Moneru," our first in-house developed product containing microalgae selected from our microalgae library. Through participation in research meetings and symposiums attended by physicians and others from medical institutions, the product has been expanded to clinics, and is currently being sold at 80 clinics nationwide. (As of July 31, 2025)
Reference:Algae] was also the topic of Dr. Tomomi Himeno's lecture! Algae supplement Moneru to exhibit at the International Symposium on Nutritional Medicine 2024
Furthermore, in 2025, the production of purely domestic, high-quality, and highly concentrated astaxanthin raw materials by the Japan Biological Science Institute began, utilizing the proprietary microalgae strains and cultivation technology developed by Algar Bio.
Reference:Astaxanthin-rich algae production to be commercialized - Joint development between AlgalBio and the Japan Biological Science Institute comes to fruition
Algar Bio will continue to contribute to improving people's health and quality of life through the discovery and development of functional raw materials using microalgae based on its proprietary "Microalgae Biofoundry Platform".
With the adoption of the JST A-STEP program, we will further accelerate our efforts to quickly commercialize algae raw materials and products with unprecedented high functionality based on scientific evidence, which will be a new option for many more people.
Outline of the Support Program for Optimum Deployment of Research Results (A-STEP)
A-STEP (Assistance Program for the Optimum Deployment of Research Results) is a support program for the practical application of research results obtained at universities and public research institutions in a manner that returns the results to society. The "Support for Implementation (Repayment Type)," which was adopted by AlgarBio, supports technologies that start-up companies aim to implement in society and encourages the creation of innovative products and services.
This program promotes innovation through development loans, aiming for early return of research results to society. Applications are consulted and selected by an evaluation committee composed of outside experts from the perspectives of novelty and superiority of the technological seeds, potential for innovation creation, R&D goals and plans, commercialization potential, financial status, etc., before development support is determined.
Development Overview
Title: "Development of Highly Functional Raw Materials from Microalgae
・Outline: Today's society is highly informatized and globalized through the Internet and smartphones, and a 24-hour society has taken root. In such a society, work and life proceed day and night without distinction, and the quality of sleep and the amount of time spent sleeping are becoming important issues.
According to the results of a 2021 survey by the Organization for Economic Cooperation and Development (OECD), Japan has the shortest average sleep duration among 33 developed countries and is positioned as a country with sleep-related problems worldwide. Furthermore, sleep disorders are becoming more serious in other countries as well, and the market for melatonin, a sleep-inducing drug, is rapidly expanding.
Against this backdrop, conventional insomnia drugs and health foods are widely used as common measures. Insomnia drugs help people fall asleep, but they tend to leave them feeling drowsy when they wake up from sleep, and their rebound effect, in which people are unable to sleep again after discontinuing taking them, is considered problematic. In recent years, insomniacs with fewer side effects have been developed, but the problem of feeling groggy in bed still remains, and a new approach without side effects is needed.
AlgalBio, which took over more than 20 years of algae research at the University of Tokyo, has established a library of more than 1,260 strains of microalgae from 100 species and is conducting further research. Among them, we have discovered a unique microalgae strain that has been shown to reduce inflammatory substances in the brain after oral ingestion in mice. Using this strain, we are developing new solutions to improve sleep and maintain cognitive function.
With the support of this project, AlgarBio will acquire the safety data necessary for notification as a food with functional claims and build evidence of efficacy, as well as elucidate the mechanism of action and conduct regulatory research for overseas development. This will further accelerate efforts toward the early commercialization of algae raw materials and products with high functionality.

About AlgalBio, Inc.
Algal Bio Inc. is a research and development venture specializing in the research, development, and commercialization of microalgae.
With the mission of "contributing to the future of people and the Earth through research and development of algae," we aim to give shape to the potential of microalgae.
Based on more than 20 years of algae research at the University of Tokyo, we have established the Microalgae Biofoundry Platform, which includes a library of more than 1,260 strains of microalgae from 100 species, breeding and selection techniques for each species, know-how on designing optimal culture conditions, and a pilot plant that can handle scale-up studies. We also have a pilot plant for scale-up studies.
Utilizing these technologies and infrastructures, we are able to quickly realize everything from the search for the optimal microalgae to its commercialization and commercialization in response to the diverse needs of our clients. Together with a wide variety of partner companies, we promote the creation of new products and solutions utilizing microalgae to address global social issues such as human health, sustainable food supply, and global warming countermeasures.
Algar Bio Inc.
| name of company | Algal Bio Inc. |
| Establishment | Mar 2018 |
| Location | 301 Tokatsu Techno Plaza, 5-4-6 Kashiwanoha, Kashiwa-shi, Chiba |
| representative | Shu Kimura |
| uniform resouce locator | https://algalbio.co.jp/ |









